Redeye reiterates its positive view on Enlabs with only minor changes to estimates and maintained fair value, despite postponed financial targets to 2021. The first quarter came in below our sales estimates much due to a low casino margin, while the number of actives impressed with a new ATH. The pending situation in Latvia takes its toll on the case and share price. However, looking beyond the Corona Crisis the growth prospect of Enlabs remains very appealing.